Image: CIDRAPBioNTech Announces Closures of German and Singapore Sites Affecting Up to 1860 Jobs
• BioNTech revealed plans to close manufacturing sites in Germany and Singapore, impacting up to 1,860 jobs, as it shifts from COVID-19 vaccine production to oncology therapies. • The company, which co-developed the mRNA vaccine Comirnaty with Pfizer, will also repurchase up to $1 billion in shares amid a leadership transition. • This restructuring reflects the post-pandemic decline in demand for COVID vaccines, positioning BioNTech to focus on cancer treatments with greater long-term potential.
cidrap.umn.edu
